{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:34:35Z","timestamp":1792802075311,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cllc.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:42:32Z","timestamp":1770136952000},"page":"259-272.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-7101","authenticated-orcid":false,"given":"Anna","family":"Minchom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Sabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamya","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mitselos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Zemlickis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alhadab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busola","family":"Sanusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Berkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland E.","family":"Knoblauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hellemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.02.001_bib0001","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0002","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2026.02.001_bib0003","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor\u2013resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2026.02.001_bib0004","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cllc.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR\u2013MET bispecific antibody, in diverse models of EGFR exon 20 insertion\u2013driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.02.001_bib0007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0008","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer: primary results from the phase III PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0010","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2024.42.3_suppl.135","article-title":"Amivantamab monotherapy in relapsed\/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b\/2 study","volume":"42","author":"Oberstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0012","doi-asserted-by":"crossref","unstructured":"Eng C, Oberstein PE, Hecht JR, et al. Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer: whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study. Poster presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.3550"},{"key":"10.1016\/j.cllc.2026.02.001_bib0013","doi-asserted-by":"crossref","unstructured":"Raghav K, Van Cutsem E, Arnold D, et al. Amivantamab with and without chemotherapy in right-sided advanced or metastatic colorectal cancer: updated results from OrigAMI-1, an open-label, phase 1b\/2 study. Poster presented at American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium; January 23-25, 2025.","DOI":"10.1200\/JCO.2025.43.4_suppl.197"},{"key":"10.1016\/j.cllc.2026.02.001_bib0014","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cllc.2026.02.001_bib0015","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non\u2013small cell lung cancer","volume":"25","author":"Yun","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2026.02.001_bib0016","unstructured":"RYBREVANT\u24c7 (amivantamab-vmjw) injection, for intravenous use. Horsham, PA, USA: Janssen Biotech, Inc.; Revised 2025. https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/RYBREVANT-pi.pdf"},{"key":"10.1016\/j.cllc.2026.02.001_sbref0017","series-title":"Rybrevant (amivantamab) 350\u202fmg concentrate for solution for infusion","year":"2024"},{"key":"10.1016\/j.cllc.2026.02.001_bib0018","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lungcan.2023.02.008","article-title":"Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study","volume":"178","author":"Park","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.02.001_bib0019","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous amivantamab-results from SKIPPirr, a phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_sbref0020","series-title":"(amivantamab and hyaluronidase-lpuj) injection, for subcutaneous use","year":"2025"},{"key":"10.1016\/j.cllc.2026.02.001_bib0021","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cpt.3064","article-title":"Determination and confirmation of recommended ph2 dose of amivantamab in epidermal growth factor receptor exon 20 insertion non\u2013small cell lung cancer","volume":"115","author":"Haddish-Berhane","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cllc.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"S1116","DOI":"10.1016\/j.jtho.2021.08.532","article-title":"P50.04 Amivantamab in combination with chemotherapy in patients with advanced non\u2013small cell lung cancer (NSCLC)","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0023","first-page":"1","article-title":"Cutaneous toxicities with amivantamab for non\u2013small cell lung cancer: a practical guide and best practices","volume":"28","author":"Singh-Kandah","year":"2024","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.cllc.2026.02.001_bib0024","unstructured":"Krebs MG, Johnson ML, Cho BC, et al. Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: initial safety and pharmacokinetic results from the PALOMA study. Presented at AACR Annual Meeting; April 8-13, 2022."},{"key":"10.1016\/j.cllc.2026.02.001_bib0025","doi-asserted-by":"crossref","unstructured":"Girard N, Cho BC, Spira AI, et al. Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non\u2013small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone. Presented at American Society of Clinical Oncology (ASCO\u24c7) Annual Meeting; June 2-6, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.9137"},{"key":"10.1016\/j.cllc.2026.02.001_bib0026","first-page":"579","article-title":"VTE with amivantamab plus chemotherapy in NSCLC","volume":"390","author":"Zhou","year":"2024","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.cllc.2026.02.001_bib0027","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jconrel.2006.05.027","article-title":"A recombinant human enzyme for enhanced interstitial transport of therapeutics","volume":"114","author":"Bookbinder","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.cllc.2026.02.001_bib0028","first-page":"1","article-title":"PEGylated recombinant human hyaluronidase (PEGPH20): transition from a novel functional excipient to an API to increase the chemotherapeutic effectiveness against hyaluronan-rich cancers","volume":"9","author":"Apte","year":"2018","journal-title":"J Excipients Food Chem"},{"key":"10.1016\/j.cllc.2026.02.001_bib0029","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lungcan.2022.09.012","article-title":"Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non\u2013small cell lung cancer harboring EGFR exon20ins: towards a proactive, multidisciplinary approach","volume":"173","author":"Basse","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.02.001_bib0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5582\/bst.2018.01246","article-title":"Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors","volume":"12","author":"Peng","year":"2019","journal-title":"Biosci Trends"},{"key":"10.1016\/j.cllc.2026.02.001_bib0031","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0032","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0033","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40487-025-00386-8","article-title":"The phase 2b COPERNICUS study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non\u2013small cell lung cancer: a vodcast","volume":"13","author":"Halmos","year":"2025","journal-title":"Oncol Ther"},{"key":"10.1016\/j.cllc.2026.02.001_bib0034","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer","volume":"78","author":"Connolly","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2011.07.004","article-title":"Lung cancer associated venous thromboembolic disease: a comprehensive review","volume":"75","author":"Corrales-Rodriguez","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.02.001_bib0036","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.02.001_bib0037","doi-asserted-by":"crossref","unstructured":"Lim SM, Tan J-L, Dias JM, et al. Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated advanced non\u2013small cell lung cancer (NSCLC): interim results from the phase 2 PALOMA-2 study. Presented at American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8612"},{"key":"10.1016\/j.cllc.2026.02.001_bib0038","doi-asserted-by":"crossref","first-page":"LBA8612","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8612","article-title":"Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non\u2013small cell lung cancer (NSCLC): results from the phase 2 PALOMA-2 study","volume":"42","author":"Lim","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0039","doi-asserted-by":"crossref","first-page":"LBA8505","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8505","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115624","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non\u2013small cell lung cancer: patient satisfaction and resource utilization results from the PALOMA-3 study","volume":"227","author":"Alexander","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.02.001_bib0041","unstructured":"Johnson & Johnson. European Commission approves subcutaneous RYBREVANT\u24c7\u25bc (amivantamab) for the treatment of patients with advanced EGFR-mutated non\u2013small cell lung cancer. Accessed February 24, 2026. https:\/\/www.jnj.com\/media-center\/press-releases\/subcutaneous-rybrevant-amivantamab-approved-by-european-commission-for-every-three-week-and-every-four-week-dosing-for-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer."},{"key":"10.1016\/j.cllc.2026.02.001_bib0042","doi-asserted-by":"crossref","first-page":"S951","DOI":"10.1016\/j.annonc.2021.08.1797","article-title":"1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study","volume":"32","author":"Leighl","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0043","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.02.001_bib0044","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/10781552221103551","article-title":"Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma","volume":"29","author":"Mateos","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.cllc.2026.02.001_bib0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.2019000667","article-title":"Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cllc.2026.02.001_bib0046","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3324\/haematol.2019.243790","article-title":"Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)","volume":"106","author":"San-Miguel","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.cllc.2026.02.001_bib0047","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non\u2013small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2026.02.001_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-med-051718-013524","article-title":"Precision management of advanced non\u2013small cell lung cancer","volume":"71","author":"Yang","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cllc.2026.02.001_bib0049","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non\u2013small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:06:36Z","timestamp":1776726396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525730426000264"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}